Gsk (GSK) Cash from Discontinued Operations (2021 - 2026)

Gsk's Cash from Discontinued Operations history runs 6 years deep, the most recent figure standing at 3609115158.55 for Q2 2026.

• In Q2 2026, Cash from Discontinued Operations rose 29.07% year-over-year to 3609115158.55; the TTM figure through Jun 2026 stood at 18442485946.88 (up 19.38% YoY), while the FY2025 annual figure was 10206588510.3, up 21.83% from the prior year.
• Cash from Discontinued Operations for Q2 2026 stood at 3609115158.55, up from 1538271553.88 in the prior quarter.
• The five-year high for Cash from Discontinued Operations was 10296816542.34 in Q4 2025, with the low at 186495603.06 in Q4 2022.
• The 5-year median for Cash from Discontinued Operations is 2215845697.94 (2025), against an average of 2833404722.56.
• The sharpest annual moves came in 2022 and 2023: Cash from Discontinued Operations slumped 124.53% in 2022, then soared 2226.98% in 2023.
• Gsk's Cash from Discontinued Operations stood at 186495603.06 in 2022, then jumped by 2226.98% to 3966721425.69 in 2023, then surged by 112.07% to 8412071055.38 in 2024, then increased by 22.41% to 10296816542.34 in 2025, then plunged by 64.95% to 3609115158.55 in 2026.
• Business Quant data shows GSK's Cash from Discontinued Operations at 3609115158.55 in Q2 2026, 1538271553.88 in Q1 2026, and 10296816542.34 in Q4 2025.